Global Non-alcoholic Steatohepatitis Market 2016-2020

This market research report includes a detailed segmentation of the global non-alcoholic steatohepatitis market by dosage form (solid and liquid) and by route of administration (oral and parenteral). It also outlines the market shares for key regions like the Americas, APAC, and Europe. The leading vendors analyzed in this report are AstraZeneca, Arena Pharmaceuticals, GlaxoSmithKline, Novo Nordisk, Roche, and Vivus.

Outlook of the global non-alcoholic steatohepatitis market

Technavio’s market research analyst predicts the global non-alcoholic steatohepatitis (NASH) market to rapidly grow at a CAGR of approximately 24% by 2020. Much of this market’s growth can be attributed to the high prevalence of obesity and diabetes among the populace. In 2014, more than 1.9 billion adults were found to be overweight. Of these, over 600 million were obese. Similarly, in 2014, the global prevalence of diabetes in adults over 18 years of age was estimated to be 9%. High incidence of these associated conditions is the major driver for the growth of this market during the forecast period.

Furthermore, the launch of novel drug candidates with a high efficacy and safety profile will have a positive effect on the growth of this market.

Product-based segmentation of the non-alcoholic steatohepatitis drugs market

• Oral
• Parenteral

In this market study, analysts have estimated the oral route of drug administration to be the most preferred route of drug ingestion for the treatment of NASH. Drugs like Forxiga/Farxiga and Komboglyze are administered through this route.

The parenteral route of administration is required during emergencies, especially when there is a need for greater patient compliance. Drugs like Actrapid, Insulatard, Levemir, and Byetta are administered through this route.

Geographical segmentation of the non-alcoholic steatohepatitis drugs market

• Americas
• APAC
• Europe

In this global market research, analysts have estimated the Americas to be the largest market for non-alcoholic steatohepatitis drugs during the forecast period. This region currently accounts for approximately 59% of the total market share and is envisaged to retain its hold over the market by 2020 owing to the high incidence of obesity and diabetes in regions like the US, Canada, and Brazil.

Competitive landscape and key vendors

The global non-alcoholic steatohepatitis market is highly competitive owing to the presence of numerous small and large players that operate on a local or global scale. The vendors in this market compete on the basis of price, quality, and innovation. The high level of competition in this market has led to an increase in the number of M&A, wherein smaller entities are being acquired by, or are being merged with, major players.

Leading vendors in the market are -

• AstraZeneca
• Arena Pharmaceuticals
• GlaxoSmithKline
• Novo Nordisk 
• Roche
• Vivus

Other prominent vendors in the market include Arisaph Pharmaceuticals, Cempra Pharmaceuticals, Galectin Therapeutics, Galmed Pharmaceuticals, Genfit, Gilead, Immuron, Interceptpharma, Raptor Pharmaceutical, Shire, Tobira Therapeutics, Verva, and Viking Therapeutics.

Key questions answered in the report include

• What will the market size and the growth rate be in 2020?
• What are the key factors driving the global non-alcoholic steatohepatitis market?
• What are the key market trends impacting the growth of the global non-alcoholic steatohepatitis market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the vendors in the global non-alcoholic steatohepatitis market?
• What are the trending factors influencing the market shares of the Americas, APAC, and Europe?
• What are the key outcomes of the five forces analysis of the global non-alcoholic steatohepatitis market?

Technavio also offers customization on reports based on specific client requirement.

Related reports

• Global Liver Diseases Therapeutics Market 2015-2019
• Global Infectious Disease Diagnostic Testing Market 2015-2019